Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ("Valneva" or the "Company"), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000. Peter Bühler, Valneva's Chief Financial Officer, commented, "We would like to thank our existing shareholders for their continued support, as well as the new healthcare specialist investors joining us through this raise. In addition to suppor ...

Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ("Valneva" or the "Company"), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the "Offer Shares") at a price of €2.66 per Offer Share to certain categories of investors via a private placement through an accelerated bookbuilding process starting immediately. Context of the Offering The Issuer intends to use the net pro ...

Valneva SE (VALN) and Pfizer Inc. recently reported positive immunogenicity and safety data from their VLA15-221 Phase 2 study. Data from the study showed a strong immune response one month after a second booster dose in pediatric and adult populations. The safety and tolerability profile of VLA15 after a second booster dose was compared with that observed after the first booster. No safety concern was observed by an independent Data Monitoring Committee ("DMC") in any treatment or age group. The new favora ...

Shares of Valneva SE Sponsored ADR (VALN) have gained 3.5% over the past four weeks to close the last trading session at $7.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.33 indicates a potential upside of 150.4%. The average comprises four short-term price targets ranging from a low of $8.30 to a high of $26, with a standard deviation of $7.63. While the lowest estimat ...

文章核心观点 - 分析师给予Valneva SE Sponsored ADR (VALN)股票的平均目标价为18.33美元,较当前价格上涨135.3%,存在较大上涨潜力 [1][2] - 分析师对公司未来盈利前景持乐观态度,纷纷上调盈利预测,这可能是推动股价上涨的合理原因 [10][11] - 分析师给出的目标价格并不一定能准确预测股价走势,投资者不应完全依赖 [3][5][9] 公司相关 - 公司当前股价为7.79美元,过去4周涨幅为0.7% [1] - 分析师给出的目标价格区间为8.30美元至26美元,标准差为7.63美元 [2] - 公司目前被评为Zacks Rank 2(买入),处于行业前20%,这进一步支持了其短期上涨潜力 [12] 行业相关 - 分析师给出的目标价格往往存在偏高倾向,这可能源于其所在券商的商业利益考虑 [6][7] - 但当分析师对某股票的目标价格预测高度一致时,可能意味着对公司基本面的普遍认同,值得进一步研究 [8]

First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasing Net Profit of €34.0 million, including proceeds from PRV sale Operating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023 Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed its cost contributions to the agr ...

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2 Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schl ...

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2 Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schl ...

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICs IXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe CEPI will provide Valneva up to U.S. $41.3 million of additional funding over th ...

Significance of the IXCHIQ Vaccine Expanding Market Potential An additional marketing authorization application is under review by the Brazilian Health Regulatory Agency to make the vaccine available in certain low- and middle-income countries, with a potential approval in 2024. Valneva's latest approval from the EC turns out to be in favor of market growth. Valneva SE (VALN) recently announced that the European Commission (EC) has given it the marketing authorization for Valneva's single-dose Chikungunya v ...